SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea flag South Korea · Delayed Price · Currency is KRW
119,600
+200 (0.17%)
Last updated: Jan 29, 2026, 2:14 PM KST

SK Biopharmaceuticals Revenue

SK Biopharmaceuticals had revenue of 191.73B KRW in the quarter ending September 30, 2025, with 40.35% growth. This brings the company's revenue in the last twelve months to 675.41B, up 32.09% year-over-year. In the year 2024, SK Biopharmaceuticals had annual revenue of 547.60B with 54.30% growth.

Revenue (ttm)
675.41B
Revenue Growth
+32.09%
P/S Ratio
13.84
Revenue / Employee
2.75B
Employees
246
Market Cap
9.35T

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2024547.60B192.70B54.30%
Dec 31, 2023354.89B108.71B44.16%
Dec 31, 2022246.18B-172.47B-41.20%
Dec 31, 2021418.64B392.65B1,510.23%
Dec 31, 202026.00B-97.85B-79.01%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
SK bioscience624.03B
PharmaResearch496.03B
Hugel404.19B
ALTEOGEN202.18B
LigaChem Biosciences159.27B
HLB Co., Ltd.80.73B
OliX Pharmaceuticals10.18B
D&D Pharmatech8.36B
Revenue Rankings